

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1.5 mg/ml oral suspension for dogs

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One ml contains:

### Active substance

Meloxicam 1.5 mg

### Excipient

Sodium benzoate 5 mg.

For the full list of excipients, see section 6.1

## **3. PHARMACEUTICAL FORM**

Oral suspension.

A yellow coloured suspension.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Dogs.

### **4.2 Indications for use, specifying the target species**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

### **4.3 Contraindications**

Do not use in pregnant or lactating animals.

Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 6 weeks of age.

### **4.4 Special warnings for each target species**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

This product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Inflacam 0.5 mg/ml oral suspension for cats should be used.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inlacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the veterinary products used previously.

#### **4.9 Amounts to be administered and administration route**

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

For longer term treatment, once clinical response has been observed (after  $\geq 4$  days), the dose of Inlacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.

Particular care should be taken with regard to the accuracy of dosing.

Shake well before use. To be administered orally either mixed with food or directly into the mouth.

The suspension can be given using the Inflacam measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.

A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

Avoid introduction of contamination during use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Not applicable.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids; oxicams.  
ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. *In vitro* and *in vivo* studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

#### **5.2 Pharmacokinetic particulars**

##### Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

##### Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

##### Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

##### Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Saccharin sodium  
Sodium carboxyl methyl cellulose  
Colloidal silicon dioxide  
Citric acid monohydrate  
Sorbitol solution  
Disodium hydrogen-phosphate dodecahydrate  
Sodium benzoate  
Honey flavour  
Purified water.

### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after first opening the immediate packaging: 6 months.

### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

15 ml HDPE bottle with a tamper resistant child proof closure or 42, 100 or 200 ml polyethylene terephthalate (PET) bottle with a tamper resistant child proof closure and two polypropylene measuring syringes: one for small dogs (up to 20 kg) and one for bigger dogs (up to 60 kg).

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/001 15 ml  
EU/2/11/134/002 42 ml  
EU/2/11/134/003 100 ml  
EU/2/11/134/004 200 ml

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011

Date of latest renewal: 09/11/2016

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Inflacam 20 mg/ml solution for injection for cattle, pigs and horses

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One ml contains:

### Active substance

Meloxicam 20 mg

### Excipient

Ethanol (96%): 159.8 mg

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Solution for injection,  
Clear yellow solution.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Cattle, pigs and horses

### 4.2 Indications for use, specifying the target species

#### Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

#### Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

#### Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

### 4.3 Contraindications

See also section 4.7.

Do not use in horses less than 6 weeks of age.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

#### **4.4 Special warnings for each target species**

Treatment of calves with Infracam 20 minutes before dehorning reduces post-operative pain. Infracam alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

##### Cattle and pigs

Can be used during pregnancy and lactation.

##### Horses

Do not use in pregnant or lactating mares.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

#### **4.9 Amounts to be administered and administration route**

##### Cattle

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

##### Pigs

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

##### Horses

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight).

For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculo – skeletal disorders, Inflacam 15 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Avoid introduction of contamination during use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose, symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

##### Cattle

Meat and offal: 15 days.

Milk: 5 days.

##### Pigs

Meat and offal: 5 days.

##### Horses

Meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by *E. coli* endotoxin administration in calves, lactating cows and pigs.

## **5.2 Pharmacokinetic particulars**

### Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg,  $C_{max}$  values of 2.1 µg/ml and 2.7 µg/ml were reached after 7.7 hours and 4 hours in young cattle and lactating cows, respectively.

After two intramuscular doses of 0.4 mg meloxicam/kg, a  $C_{max}$  value of 1.9 µg/ml was reached after 1 hour in pigs.

### Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

### Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive. The metabolism in horses has not been investigated.

### Elimination

Meloxicam is eliminated with a half-life of 26 hours and 17.5 hours after subcutaneous injection in young cattle and lactating cows, respectively.

In pigs, after intramuscular administration the mean plasma elimination half-life is approximately 2.5 hours.

In horses, after intravenous injection meloxicam is eliminated with a terminal half-life of 8.5 hours. Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

- Ethanol (96%)
- Poloxamer 188
- Macrogol 400
- Glycine
- Sodium hydroxide
- Hydrochloric acid, concentrated
- Meglumine
- Water for injections.

### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 5 years.

Shelf life after first opening the immediate packaging: 28 days.

### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

## **6.5 Nature and composition of immediate packaging**

Cardboard box with 1 colourless glass injection vial containing 20 ml, 50 ml, 100 ml or 250 ml. Each vial is closed with a rubber stopper and sealed with an aluminium cap.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/005 20 ml  
EU/2/11/134/006 50 ml  
EU/2/11/134/007 100 ml  
EU/2/11/134/008 250 ml

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011  
Date of latest renewal: 09/11/2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 15 mg/ml oral suspension for horses

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One ml contains:

### Active substance

Meloxicam 15 mg

### Excipient

Sodium benzoate 5 mg.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Oral suspension.

White to off-white viscous oral suspension.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Horses

### **4.2 Indications for use, specifying the target species**

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.

### **4.3 Contraindications**

Do not use in pregnant or lactating mares.

Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in horses less than 6 weeks of age.

### **4.4 Special warnings for each target species**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Isolated cases of adverse reactions typically associated with NSAIDs were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible.

In very rare cases loss of appetite, lethargy, abdominal pain and colitis have been reported.

In very rare cases anaphylactoid reactions which may be serious (including fatal), may occur and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in this species is not recommended during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

#### **4.9 Amounts to be administered and administration route**

To be administered either mixed with food or directly into the mouth at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days. In case the product is mixed with food, it should be added to a small quantity of food, prior to feeding.

The suspension should be given using the Inflacam measuring syringe provided in the package. The syringe fits onto the bottle and has a 2 ml scale.

Shake well before use.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Avoid introduction of contamination during use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Meat and offal: 3 days.

Not authorised for use in lactating animals producing milk for human consumption.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Anti-inflammatory and Anti-rheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by intravenous *E. coli* endotoxin administration in calves and pigs.

#### **5.2 Pharmacokinetic particulars**

##### Absorption

When the product is used according to the recommended dosage regime, the oral bioavailability is approximately 98%. Maximal plasma concentrations are obtained after approximately 2–3 hours. The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.

##### Distribution

Approximately 98% of meloxicam is bound to plasma proteins. The volume of distribution is 0.12 l/kg.

##### Metabolism

The metabolism is qualitatively similar in rats, mini-pigs, humans, cattle and pigs, although quantitatively there are differences. The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxalyl- metabolite. The metabolism in horses was not investigated. All major metabolites have been shown to be pharmacologically inactive.

##### Elimination

Meloxicam is eliminated with a terminal half-life of 7.7 hours.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Saccharin sodium  
Carmellose sodium  
Silica, colloidal anhydrous  
Citric acid monohydrate  
Sorbitol, liquid (non-crystallising)  
Disodium phosphate dodecahydrate  
Sodium benzoate  
Honey aroma  
Purified water

#### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after first opening of the immediate packaging: 3 months.

### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

HDPE bottle containing 100 or 250 ml with a tamper proof child resistant closure and a polypropylene measuring syringe.

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Limited  
Loughrea,  
Co. Galway,  
Ireland.

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/009 100 ml  
EU/2/11/134/010 250 ml

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011  
Date of latest renewal: 09/11/2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1 mg chewable tablets for dogs  
Inflacam 2.5 mg chewable tablets for dogs

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One chewable tablet contains:

### Active substance

Meloxicam 1 mg  
Meloxicam 2.5 mg.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Chewable tablets.  
Pale-yellow, single-scored, chewable tablets.  
The tablet can be divided into equal halves.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Dogs

### **4.2 Indications for use, specifying the target species**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.

### **4.3 Contraindications**

Do not use in pregnant or lactating animals.  
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.  
Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.  
Do not use in case of hypersensitivity to the active substance or to any of the excipients.

### **4.4 Special warnings**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

This product for dogs should not be used in cats as it is not suitable for use in this species.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDS) should avoid contact with the veterinary medicinal product.

In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.

In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inlacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such medicines should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

#### **4.9 Amounts to be administered and administration route**

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.

Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively.

Each chewable tablet can be halved for accurate dosing according to the individual body weight of the dog.

Inlacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

Body weight (kg)	Number of chewable tablets		mg/kg
	1 mg	2.5mg	
4.0–7.0	½		0.13–0.1
7.1–10.0	1		0.14–0.1
10.1–15.0	1½		0.15–0.1
15.1–20.0	2		0.13–0.1
20.1–25.0		1	0.12–0.1
25.1–35.0		1½	0.15–0.1
35.1–50.0		2	0.14–0.1

The use of Inflacam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Inflacam oral suspension for dogs is recommended.

A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Not applicable.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-I).

#### **5.2 Pharmacokinetic particulars**

##### Absorption

Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 4.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

##### Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

##### Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

### Elimination

Meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Lactose monohydrate  
Silicified microcrystalline cellulose  
Sodium acid citrate  
Crospovidone  
Talc  
Pork flavour  
Magnesium stearate

### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 5 years.

### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

PVC/PVDC blister packs with a 20 micron foil.

Pack sizes: 20 and 100 tablets.

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/011  
EU/2/11/134/012

EU/2/11/134/013  
EU/2/11/134/014

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011  
Date of latest renewal: 09/11/2016

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for dogs and cats

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One ml contains:

### Active substance

Meloxicam 5 mg

### Excipient(s)

Ethanol (96%) 159.8 mg.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Solution for injection.

Clear yellow solution.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Dogs and cats.

### **4.2 Indications for use, specifying the target species**

#### Dogs

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

#### Cats

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

### **4.3 Contraindications**

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

Refer to section 4.7.

### **4.4 Special warnings for each target species**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

Any oral follow-up therapy using meloxicam or other NSAIDs should not be administered in cats, as appropriate dosage regimens for such follow-up treatments have not been established.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases elevated liver enzymes have been reported.

In very rare cases, haemorrhagic diarrhoea, haematemesis, and gastrointestinal ulceration have been reported.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Do not use in pregnant or lactating animals.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inlacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

#### **4.9 Amounts to be administered and administration route**

Maximum number of piercings is 42 for all presentations.

## Dogs

Musculo-skeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight).

Inflacam 1.5 mg/ml oral suspension for dogs or Inflacam 1 mg and 2.5 mg chewable tablets for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours):

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia.

## Cats

Reduction of post-operative pain:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia.

Particular care should be taken with regard to the accuracy of dosing.

Avoid introduction of contamination during use.

### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose symptomatic treatment should be initiated.

### **4.11 Withdrawal period(s)**

Not applicable.

## **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. *In vitro* and *in vivo* studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

### **5.2 Pharmacokinetic particulars**

#### Absorption

Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 µg/ml in dogs and 1.1 µg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively.

#### Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range in dogs. More than 97 % of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg in dogs and 0.09 l/kg in cats.

### Metabolism

In dogs, meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

In cats, meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Five major metabolites were detected all having been shown to be pharmacologically inactive. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation.

### Elimination

In dogs, meloxicam is eliminated with a half-life of 24 hours. Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.

In cats, meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21 % of the recovered dose is eliminated in urine (2 % as unchanged meloxicam, 19 % as metabolites) and 79% in the faeces (49 % as unchanged meloxicam, 30 % as metabolites).

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Ethanol (96%)  
Poloxamer 188  
Macrogol 400  
Glycine  
Disodium edetate  
Sodium hydroxide  
Hydrochloric acid, concentrated  
Meglumine  
Water for injections

### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 5 years.

Shelf life after first opening the immediate packaging: 28 days.

### **6.4 Special precautions for storage**

Keep the vial in the outer carton.

### **6.5 Nature and composition of immediate packaging**

Carton box containing one colourless glass injection vial of 10 ml, 20 ml or 100ml, closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Limited  
Loughrea,  
Co. Galway,  
Ireland.

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/015 10 ml  
EU/2/11/134/016 20 ml  
EU/2/11/134/017 100ml

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011  
Date of latest renewal: 09/11/2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Inflacam 5 mg/ml solution for injection for cattle and pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One ml contains:

### Active substance

Meloxicam 5 mg

### Excipient

Ethanol (96%) 159.8 mg.

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Solution for injection.

Clear yellow solution.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Cattle (calves and young cattle) and pigs.

### 4.2 Indications for use, specifying the target species

#### Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

#### Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For the relief of post-operative pain associated with minor soft tissue such as castration.

### 4.3 Contraindications

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

Do not use in pigs less than 2 days old.

#### **4.4 Special warnings for each target species**

Treatment of calves with Inflacam 20 minutes before dehorning reduces post-operative pain. Inflacam alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Treatment of piglets with Inflacam before castration reduces post-operative pain. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

To obtain the best possible pain relieving post-surgery Inflacam should be administered 30 minutes before surgical intervention.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Cattle: Can be used during pregnancy.

Pigs: Can be used during pregnancy and lactation

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

#### **4.9 Amounts to be administered and administration route**

##### Cattle

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

## Pigs

### Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

### Reduction of post-operative pain

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of body weight.

Avoid introduction of contamination during use.

## **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose symptomatic treatment should be initiated.

## **4.11 Withdrawal period(s)**

### Cattle

Meat and offal: 15 days.

### Pigs

Meat and offal: 5 days.

## **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

### **5.1 Pharmacodynamic properties**

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by *E. coli* endotoxin administration in calves and pigs.

### **5.2 Pharmacokinetic particulars**

#### Absorption

After a single subcutaneous dose of 0.5 mg meloxicam/kg,  $C_{max}$  values of 2.1 µg/ml were reached after 7.7 hours in young cattle.

Following single intramuscular doses of 0.4 mg meloxicam/kg, a  $C_{max}$  value of 1.1 to 1.5 µg/ml was reached within 1 hour in pigs.

#### Distribution

More than 98 % of meloxicam is bound to plasma proteins. The highest meloxicam concentrations are to be found in liver and kidney. Comparatively low concentrations are detectable in skeletal muscle and fat.

#### Metabolism

Meloxicam is predominantly found in plasma. In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. In pigs, bile and urine contain only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

### Elimination

Meloxicam is eliminated with a half-life of 26 hours after subcutaneous injection in young cattle. In pigs, after intramuscular administration the mean plasma elimination half-life is approximately 2.5 hours.

Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

- Ethanol (96%)
- Poloxamer 188
- Macrogol 400
- Glycine
- Disodium edetate
- Sodium hydroxide
- Hydrochloric acid, concentrated
- Meglumine
- Water for injections

### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 5 years.  
Shelf life after first opening the immediate packaging: 28 days.

### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

Carton box containing 1 colourless glass injection vial of 20 ml, 50 ml or 100 ml, closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/018 20 ml  
EU/2/11/134/019 50 ml  
EU/2/11/134/020 100 ml

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011  
Date of latest renewal: 09/11/2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 330 mg granules for horses

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One sachet contains:

### Active substance

Meloxicam 330 mg.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Granules in sachet.  
Pale yellow granules.

## **4. CLINICAL PARTICULARS**

### **4.1 Target species**

Horses.

### **4.2 Indications for use, specifying the target species**

Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.

### **4.3 Contraindications**

Do not use in pregnant or lactating mares.  
Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.  
Do not use in case of hypersensitivity to the active substance or to any of the excipients.  
Do not use in horses less than 6 weeks of age.

### **4.4 Special warnings for each target species.**

None.

### **4.5 Special precautions for use**

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

In order to minimise risk of intolerance, the product should be mixed into muesli feed.

This product is only for use in horses weighing between 500 and 600 kg.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Isolated cases of adverse reactions typically associated with NSAIDs were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible. In very rare cases loss of appetite, lethargy, abdominal pain and colitis have been reported.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Laboratory studies in cattle have not provided any evidence for teratogenic, foetotoxic, or maternotoxic effects. However, no data have been generated in horses. Therefore the use in horses is not recommended during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Do not administer concurrently with glucocorticoids, other NSAIDs or with anti-coagulant agents.

#### **4.9 Amounts to be administered and administration route**

In-feed use.

To be administered mixed with food at a dose of 0.6 mg/kg body weight, once daily, up to 14 days. The product should be added to 250 g of muesli feed, prior to feeding.

Each sachet contains one dose for a horse weighing between 500 and 600 kg and the dose must not be divided into smaller doses.

Avoid introduction of contamination during use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

In the case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Meat and offal: 3 days.

Not authorised for use in lactating animals producing milk for human consumption.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Anti-inflammatory and anti-rheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

## 5.1 Pharmacodynamic properties

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B<sub>2</sub> induced by intravenous *E. coli* endotoxin administration in calves and pigs.

## 5.2 Pharmacokinetic particulars

### Absorption

When the product is used according to the recommended dosage regime, the oral bioavailability is approximately 98%. Maximal plasma concentrations are obtained after approximately 2–3 hours. The accumulation factor of 1.08 suggests that meloxicam does not accumulate when administered daily.

### Distribution

Approximately 98% of meloxicam is bound to plasma proteins. The volume of distribution is 0.12 l/kg.

### Metabolism

The metabolism is qualitatively similar in rats, humans, cattle and pigs (including mini-pigs), although quantitatively there are differences. The major metabolites found in all species were the 5-hydroxy- and 5-carboxy- metabolites and the oxaly- metabolite. The metabolism in horses was not investigated. All major metabolites have been shown to be pharmacologically inactive.

### Elimination

Meloxicam is eliminated with a terminal half-life of 7.7 hours.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Glucose monohydrate  
Povidone  
Apple flavour (containing butylated hydroxyanisole (E320))  
Crospovidone

### 6.2 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### 6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after incorporation into muesli feed: use immediately.

### 6.4 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

### 6.5 Nature and composition of immediate packaging

Paper foil sachets (paper/PE/alu/PE) containing 1.5 g granules per sachet in a cardboard box.  
Pack size: 20 and 100 sachets.

Not all pack sizes may be marketed.

**6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Limited  
Loughrea,  
Co. Galway,  
IRELAND.

**8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/021  
EU/2/11/134/022

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011  
Date of latest renewal: 09/11/2016

**10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Inflacam 0.5 mg/ml oral suspension for cats

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One ml contains:

### Active substance

Meloxicam 0.5 mg

### Excipient

Sodium benzoate 1.5 mg

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Oral suspension.

A smooth light yellow suspension.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Cats.

### 4.2 Indications for use, specifying the target species

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.

Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.

### 4.3 Contraindications

Do not use in pregnant or lactating animals.

Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cats less than 6 weeks of age.

### 4.4 Special warnings for each target species

None.

### 4.5 Special precautions for use

#### Special precautions for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

#### Post-operative pain and inflammation following surgical procedures:

In case additional pain relief is required, multimodal pain therapy should be considered.

#### Chronic musculoskeletal disorders:

Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

People with known hypersensitivity to non-steroidal anti-Inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. Gastrointestinal ulceration and elevated liver enzymes were reported in very rare cases.

These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3).

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inflacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic veterinary medicinal products should be avoided.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

#### **4.9 Amounts to be administered and administration route**

Oral use.

#### Post-operative pain and inflammation following surgical procedures:

After initial treatment with Inflacam 5 mg/ml solution for injection for cats, continue treatment 24 hours later with Inflacam 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight (0.1 ml /kg). The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days.

#### Acute musculo-skeletal disorders:

Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight (0.4 ml/kg) on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight (0.1 ml /kg) for as long as acute pain and inflammation persist.

#### Chronic musculo-skeletal disorders:

Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight (0.2 ml/kg) on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight (0.1 ml /kg). A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

#### Route and method of administration

A one ml syringe is provided with the product. The precision of the syringe is not suitable for the treatment of cats below 1 kg.

Shake well before use. To be administered orally either mixed with food or directly into the mouth.

Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.

Avoid introduction of contamination during use.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.

In case of overdose, adverse reactions, as listed in section 4.6, are expected to be more severe and more frequent. In case of overdose symptomatic treatment should be initiated.

#### **4.11 Withdrawal period(s)**

Not applicable.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams).  
ATCvet code: QM01AC06.

#### **5.1 Pharmacodynamic properties**

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. *In vitro* and *in vivo* studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

#### **5.2 Pharmacokinetic particulars**

##### Absorption

If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed.

##### Distribution

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins.

### Metabolism

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Five major metabolites were detected all having been shown to be pharmacologically inactive. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation.

### Elimination

Meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21% of the recovered dose is eliminated in urine (2% as unchanged meloxicam, 19% as metabolites) and 79% in the faeces (49% as unchanged meloxicam, 30% as metabolites).

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium benzoate  
Glycerol  
Citric acid monohydrate  
Xanthan gum  
Sodium dihydrogen phosphate monohydrate  
Simethicone emulsion  
Honey flavour  
Silica, colloidal anhydrous  
Water, purified

### **6.2 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary products.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 30 months

#### Shelf life after first opening the immediate packaging:

3 ml and 5 ml bottle:	14 days
10 ml and 15 ml bottle:	6 months.

### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

### **6.5 Nature and composition of immediate packaging**

White high density polyethylene bottle containing 10 ml or 15 ml with a tamper proof child resistant closure.

Polypropylene bottle containing 3 ml or 5 ml with a tamper proof child resistant closure.

Each bottle is packed in a cardboard box with a 1 ml measuring syringe (barrel in polypropylene and plunger/piston in high density polyethylene).

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway, Ireland.

## **8. MARKETING AUTHORISATION NUMBERS**

EU/2/11/134/023	10 ml
EU/2/11/134/024	15 ml
EU/2/11/134/025	3 ml
EU/2/11/134/026	5 ml

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 09/12/2011

Date of last renewal: 09/11/2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

**ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

## A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Chanelle Pharmaceuticals Manufacturing Limited

Loughrea

Co. Galway

IRELAND

**For Inflacam 20 mg/ml solution for injection for cattle, pigs and horses and Inflacam 5 mg/ml solution for injection for cats and dogs and Inflacam 5 mg/ml solution for injection for cattle and pigs only:**

Eurovet Animal Health B.V.

Handelsweg 25,

5531 AE Bladel,

The Netherlands

and

Labiana Life Sciences, S.A., C/ Venus, 26, Pol. Ind. Can Parellada, Tarrasa, 08228 Barcelona

## B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

## C. STATEMENT OF THE MRLs

The active substance in Inflacam is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) 37/2010:

Pharmacologically active substance	Marker residue	Animal species	MRL	Target tissues	Other provisions	Therapeutic classification
Meloxicam	Meloxicam	Bovine, caprine, porcine, rabbit, <i>Equidae</i>	20 µg/kg 65 µg/kg 65 µg/kg	Muscle Liver Kidney	NO ENTRY	Anti-inflammatory agents/Nonsteroidal anti-inflammatory agents
		Bovine, caprine	15 µg/kg	Milk		

The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Carton for 15 ml, 42 ml, 100 ml or 200 ml bottle

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1.5 mg/ml oral suspension for dogs  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains: 1.5 mg of meloxicam,  
5 mg of sodium benzoate.

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

15 ml  
42 ml  
100 ml  
200 ml

**5. TARGET SPECIES**

Dogs.

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Shake well before use.  
To be administered mixed with food or directly into the mouth.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Do not use in pregnant or lactating animals.

**10. EXPIRY DATE**

EXP {month/year}

Once opened use within 6 months.

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/001 15 ml  
EU/2/11/134/002 42 ml  
EU/2/11/134/003 100 ml  
EU/2/11/134/004 200 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN{number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Label for 15 ml and 42 ml bottle**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1.5 mg/ml oral suspension for dogs  
Meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 1.5 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

15 ml  
42 ml

**4. ROUTE(S) OF ADMINISTRATION**

Shake well before use.  
To be administered mixed with food.

**5. WITHDRAWAL PERIOD(S)**

**6. BATCH NUMBER**

BN {number}

**7. EXPIRY DATE**

EXP {month/year}  
Once opened use within 6 months.

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Label for 100 ml and 200 ml bottles**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1.5 mg/ml oral suspension for dogs  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains: 1.5 mg of meloxicam,  
5 mg of sodium benzoate.

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

100 ml  
200 ml

**5. TARGET SPECIES**

Dogs.

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Shake well before use.  
Avoid introduction of contamination during use.  
To be administered mixed with food or directly into the mouth.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Do not use in pregnant or lactating animals.

**10. EXPIRY DATE**

EXP {month/year}

Once opened use within 6 months.

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only-to be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/003 100 ml

EU/2/11/134/004 200 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN{number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton for 20 ml, 50 ml, 100 ml and 250 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml,  
Ethanol (96%) 159.8 mg/ml.

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

20 ml  
50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATIONS**

Read the package leaflet before use.

**7. METHOD AND ROUTES OF ADMINISTRATION**

Cattle

Single subcutaneous or intravenous injection.

Pigs

Single intramuscular injection. If required, a second administration can be given after 24 hours.

Horses

Single intravenous injection.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:

Cattle: meat and offal: 15 days; milk: 5 days.

Pigs: meat and offal: 5 days.

Horses: meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP { month/year }

Shelf life after first opening the immediate packaging: 28 days.

Once broached, use by...

**11. SPECIAL STORAGE CONDITIONS****12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OF RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/005 20 ml  
EU/2/11/134/006 50 ml  
EU/2/11/134/007 100 ml

EU/2/11/134/008 250 ml

**17. MANUFACTURER'S BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Label for 50 ml, 100 ml and 250 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 20 mg/ml,  
Ethanol (96%) 159.8 mg/ml.

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

50 ml  
100 ml  
250 ml

**5. TARGET SPECIES**

Cattle, pigs and horses

**6. INDICATIONS**

Read package leaflet before use.

**7. METHOD AND ROUTES OF ADMINISTRATION**

Cattle  
SC or IV injection.

Pigs  
IM injection.

Horses  
IV injection.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Cattle: meat and offal: 15 days; milk: 5 days.  
Pigs: meat and offal: 5 days.

Horses: meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP { month/year }

Shelf life after first opening the immediate packaging: 28 days.

Once broached, use by...

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OF RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only-to be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/006 50 ml  
EU/2/11/134/007 100 ml  
EU/2/11/134/008 250 ml

**17. MANUFACTURER’S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Label for 20 ml bottles**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 20 mg/ml,

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

20 ml

**4. ROUTES OF ADMINISTRATION**

Cattle  
SC or IV injection.

Pigs  
IM injection.

Horses  
IV injection.

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Cattle: meat and offal: 15 days; milk: 5 days.  
Pigs: meat and offal: 5 days.  
Horses: meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

**6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP {month/year}  
Shelf life after first opening the immediate packaging: 28 days.  
Once broached use by ...

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton for 100 ml or 250 ml bottle**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 15 mg/ml oral suspension for horses  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains: 15 mg of meloxicam,  
5 mg of sodium benzoate.

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

100 ml  
250 ml

**5. TARGET SPECIES**

Horses.

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Shake well before use.  
To be administered either mixed with a small quantity of food, prior to feeding, or directly into the mouth.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Meat and offal: 3 days.  
Not authorised for use in lactating animals producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Do not use in pregnant or lactating mares.

**10. EXPIRY DATE**

EXP {month/year}

Once opened use within 3 months.

**11. SPECIAL STORAGE CONDITIONS**

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/009 100 ml

EU/2/11/134/010 250 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN{number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Label for 100 ml and 250 ml bottles**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 15 mg/ml oral suspension for horses  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains: 15 mg of meloxicam,  
5 mg of sodium benzoate.

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

100 ml  
250 ml

**5. TARGET SPECIES**

Horses.

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Shake well before use.  
Avoid introduction of contamination during use.  
To be administered either mixed with a small quantity of food, prior to feeding, or directly into the mouth.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Meat and offal: 3 days.  
Not authorised for use in lactating animals producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Do not use in pregnant or lactating mares.

**10. EXPIRY DATE**

EXP {month/year}

Once opened use within 3 months.

**11. SPECIAL STORAGE CONDITIONS**

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/009 100 ml

EU/2/11/134/010 250 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN{number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1 mg chewable tablets for dogs  
Inflacam 2.5 mg chewable tablets for dogs  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each chewable tablet contains:

Meloxicam 1 mg  
Meloxicam 2.5 mg

**3. PHARMACEUTICAL FORM**

Chewable tablet

**4. PACKAGE SIZE**

20 tablets  
100 tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/011 1 mg, 20 tablets  
EU/2/11/134/012 1 mg, 100 tablets  
EU/2/11/134/013 2.5 mg 20 tablets  
EU/2/11/134/014 2.5 mg, 100 tablets

**17. MANUFACTURER’S BATCH NUMBER**

BN

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**Blister**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1 mg chewable tablets for dogs  
Inflacam 2.5 mg chewable tablets for dogs  
Meloxicam

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

BN

**5. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton for 10 ml, 20 ml and 100 ml vial**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for dogs and cats  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam: 5 mg/ml,  
Ethanol (96%): 159.8 mg/ml.

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

10 ml  
20 ml  
100 ml

**5. TARGET SPECIES**

Dogs and cats

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Dogs: Musculo-skeletal disorders: single subcutaneous injection.  
Post-operative pain: single intravenous or subcutaneous injection.

Cats: Post-operative pain: single subcutaneous injection.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Do not use in pregnant or lactating animals.

**10. EXPIRY DATE**

EXP {month/year}

Shelf-life of broached vial: 28 days.

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton.

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/015 10 ml  
EU/2/11/134/016 20 ml  
EU/2/11/134/017 100 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Label for 100 ml vials**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for cats and dogs  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam: 5 mg/ml,  
Ethanol (96%): 159.8 mg/ml.

**3. PHARMACEUTICAL FORM**

Solution for injection.

**4. PACKAGE SIZE**

100 ml

**5. TARGET SPECIES**

Dogs and cats

**6. INDICATIONS**

Read package leaflet before use.

**7. METHOD AND ROUTE OF ADMINISTRATION**

Dogs: Musculo-skeletal disorders: single subcutaneous injection.  
Post-operative pain: single intravenous or subcutaneous injection.

Cats: Post-operative pain: single subcutaneous injection.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Shelf life after first opening the immediate packaging: 28 days.

Once broached, use by...

**11. SPECIAL STORAGE CONDITIONS**

Keep the vial in the outer carton.

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OF RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/017 100 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Label for 10 ml and 20 ml vials**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for dogs and cats  
Meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 5 mg/ml.

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

10 ml  
20 ml

**4. ROUTE(S) OF ADMINISTRATION**

Dogs: IV or SC.  
Cats: SC.

**5. WITHDRAWAL PERIOD(S)**

Not applicable.

**6. BATCH NUMBER**

BN {number}

**7. EXPIRY DATE**

EXP {month/year}  
Once broached, use by...

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Carton for 20 ml, 50 ml and 100 ml vial**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for cattle and pigs  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam: 5 mg/ml,  
Ethanol (96%): 159.8 mg/ml.

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

20 ml  
50 ml  
100 ml

**5. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Cattle

Single subcutaneous or intravenous injection.

Pigs

Single intramuscular injection. If required, a second administration can be given after 24 hours.

Single intramuscular injection before surgery.

Take care of accurate dosing, use of appropriate dosing device and estimation of body weight.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:

Cattle: meat and offal: 15 days.

Pigs: meat and offal: 5 days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use

**10. EXPIRY DATE**

EXP {month/year}

Shelf-life of broached vial: 28 days.

Once broached, use by.....

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
Ireland.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/018 20 ml

EU/2/11/134/019 50 ml

EU/2/11/134/020 100 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

**Label for 100 ml**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for cattle and pigs  
Meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 5 mg/ml

**3. PHARMACEUTICAL FORM**

Solution for injection

**4. PACKAGE SIZE**

100 ml

**5. TARGET SPECIES**

Cattle (calves and young cattle) and pigs

**6. INDICATIONS**

Read package leaflet before use.

**7. METHOD AND ROUTES OF ADMINISTRATION**

Cattle: SC or IV injection.

Pigs: IM injection.

Read the package leaflet before use

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:

Cattle: meat and offal: 15 days.

Pigs: meat and offal: 5 days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}  
Once broached, use by...

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OF RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.  
Loughrea  
Co. Galway  
Ireland

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/020 100 ml

**17. MANUFACTURER’S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Label for 20 ml and 50 ml bottles**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for cattle and pigs  
Meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 5 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

20 ml  
50 ml

**4. ROUTES OF ADMINISTRATION**

Cattle: SC or IV.  
Pigs: IM.

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Cattle: meat and offal: 15 days.  
Pigs: meat and offal: 5 days.

**6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP {month/year}  
Once broached use by ...

**8. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box (100s)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 330 mg, granules for horses.  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

One sachet contains: 330 mg of meloxicam.

**3. PHARMACEUTICAL FORM**

Granules in sachet

**4. PACKAGE SIZE**

100 sachets

**5. TARGET SPECIES**

Horses.

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

In-feed use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Meat and offal: 3 days.  
Not authorised for use in lactating animals producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Each sachet contains one dose for a horse weighing 500 kg - 600 kg. The dose must not be divided.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
IRELAND.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/021

**17. MANUFACTURER’S BATCH NUMBER**

BN{number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box (20s)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 330 mg, granules for horses.  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

One sachet contains: 330 mg of meloxicam.

**3. PHARMACEUTICAL FORM**

Granules in sachet

**4. PACKAGE SIZE**

20 sachets

**5. TARGET SPECIES**

Horses.

**6. INDICATION(S)**

Read the package leaflet before use.

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

In-feed use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Meat and offal: 3 days.  
Not authorised for use in lactating animals producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
IRELAND.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/022

**17. MANUFACTURER’S BATCH NUMBER**

BN{number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Sachet**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 330 mg, granules for horses.  
meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 330 mg

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

**4. ROUTE(S) OF ADMINISTRATION**

In-feed use

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period:  
Meat and offal: 3 days.  
Not authorised for use in lactating animals producing milk for human consumption.

**6. BATCH NUMBER**

BN {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Cardboard box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 0.5 mg/ml oral suspension for cats  
meloxicam

**2. STATEMENT OF ACTIVE SUBSTANCES**

Meloxicam 0.5 mg/ml

**3. PHARMACEUTICAL FORM**

Oral suspension

**4. PACKAGE SIZE**

3 ml  
5 ml  
10 ml  
15 ml

**5. TARGET SPECIES**

Cats.

**6. INDICATION(S)**

**7. METHOD AND ROUTE OF ADMINISTRATION**

Shake well before use.  
Oral use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

3 ml: Once opened use within 14 days.

5 ml: Once opened use within 14 days.

10 ml: Once opened use within 6 months.

15 ml: Once opened use within 6 months.

**11. SPECIAL STORAGE CONDITIONS****12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
IRELAND.

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/134/023 10 ml

EU/2/11/134/024 15 ml

EU/2/11/134/025 3 ml

EU/2/11/134/026 5 ml

**17. MANUFACTURER’S BATCH NUMBER**

BN{number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Bottle**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 0.5 mg/ml oral suspension for cats  
meloxicam

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Meloxicam 0.5 mg/ml

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

3 ml  
5 ml  
10 ml  
15 ml

**4. ROUTE OF ADMINISTRATION**

Oral use

**5. WITHDRAWAL PERIOD(S)**

**6. BATCH NUMBER**

BN {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**  
**Inflacam 1.5 mg/ml oral suspension for dogs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:  
Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway, Ireland.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1.5 mg/ml oral suspension for dogs  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One ml contains: 1.5 mg of meloxicam,  
5 mg of sodium benzoate.

**4. INDICATION(S)**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

**5. CONTRAINDICATIONS**

Do not use in pregnant or lactating animals.  
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.  
Do not use in case of hypersensitivity to the active substance or to any of the excipients.  
Do not use in dogs less than 6 weeks of age.

**6. ADVERSE REACTIONS**

Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Dogs.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Dosage

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

### Method and route of administration

Shake well before use. To be administered orally either mixed with food or directly into the mouth. The suspension can be given using the measuring syringe provided in the package. The syringe has a scale which corresponds to the volume required.

For initiation of the therapy on the first day, twice the maintenance dosage will be required. A clinical response is normally seen within 3 to 4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Particular care should be taken with regard to the accuracy of dosing. Please carefully follow the instructions of the veterinarian. Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.  
This veterinary medicinal product does not require any special storage conditions.  
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after 'EXP'.  
Shelf life after first opening the immediate packaging: 6 months.

## **12. SPECIAL WARNING(S)**

### Precaution for use in animals

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

This product for dogs should not be used in cats as it is not suitable for use in this species. . In cats, Inflacam 0.5 mg/ml oral suspension for cats should be used.

#### Precautions to be taken by the person administering the product

People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.

#### Use during pregnancy and lactation

See section "Contraindications".

#### Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inlacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the veterinary products used previously.

#### Overdose

In case of overdose symptomatic treatment should be initiated.

### **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>

### **15. OTHER INFORMATION**

To be supplied only on veterinary prescription.

15, 42, 100 or 200 ml bottle with two measuring syringes.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**  
Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**  
VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**  
VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**  
VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**  
Virbac Danmark  
A/S, Profilvej 1, DK-6000  
Kolding, Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**  
VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**  
VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)800 73 09 10

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**PACKAGE LEAFLET:**  
**Inflacam 20 mg/ml solution for injection for cattle, pigs and horses**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway, Ireland

Manufacturers responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway, Ireland

and

Eurovet Animal Health B.V.  
Handelsweg 25, 5531 AE Bladel, The Netherlands

and

Labiana Life Sciences, S.A., C/ Venus, 26, Pol. Ind. Can Parellada, Tarrasa, 08228 Barcelona

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 20 mg/ml solution for injection for cattle, pigs and horses  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

One ml contains:

Meloxicam           20 mg,  
Ethanol (96%)      159.8 mg.  
Clear, yellow solution.

**4. INDICATION(S)**

Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.

For the relief of post-operative pain following dehorning in calves.

Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.

For adjunctive therapy in the treatment of puerperal septicaemia and toxæmia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.

### Horses

For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.

For the relief of pain associated with equine colic.

## **5. CONTRAINDICATIONS**

Do not use in horses less than 6 weeks of age.

Do not use in pregnant or lactating mares.

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

## **6. ADVERSE REACTIONS**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In horses, a transient swelling at the injection site can occur but resolves without intervention.

In very rare cases anaphylactoid reactions may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Cattle, pigs and horses

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Cattle

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### Pigs

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. If required, a second administration of meloxicam can be given after 24 hours.

### Horses

Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight).

For use in the alleviation of inflammation and the relief of pain in both acute and chronic musculo-skeletal disorders, Inlacam 15 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.6 mg meloxicam/kg body weight, 24 hours after administration of the injection.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD(S)**

Cattle: meat and offal: 15 days; milk: 5 days.

Pigs: meat and offal: 5 days.

Horses: meat and offal: 5 days.

Not authorised for use in horses producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use after the expiry date (EXP) stated on the carton and vial.

Shelf life after first opening the container: 28 days.

## **12. SPECIAL WARNING(S)**

Treatment of calves with Inlacam 20 minutes before dehorning reduces post-operative pain. Inlacam alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

### Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

In case of inadequate relief of pain when used in the treatment of equine colic, careful re-evaluation of the diagnosis should be made as this could indicate the need for surgical intervention.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

### Use during pregnancy and lactation:

Cattle and pigs: Can be used during pregnancy and lactation.

Horses: See section "Contraindications".

### Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

### Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose, symptomatic treatment should be initiated.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**15. OTHER INFORMATION**

Cardboard box containing one colourless glass injection vial of 20 ml, 50 ml, 100 ml or 250 ml.  
Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**  
Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**  
VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**  
VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**  
VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**  
Virbac Danmark  
A/S, Profilvej 1, DK-6000  
Kolding, Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**  
VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**  
VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)800 73 09 10

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**PACKAGE LEAFLET:**  
**Inflacam 15 mg/ml oral suspension for horses**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:  
Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway, Ireland.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 15 mg/ml oral suspension for horses  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One ml contains: 15 mg of meloxicam,  
5 mg of sodium benzoate.

**4. INDICATION(S)**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in horses.

**5. CONTRAINDICATIONS**

Do not use in pregnant or lactating mares.  
Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.  
Do not use in case of hypersensitivity to the active substance or to any of the excipients.  
Do not use in horses less than 6 weeks of age.

**6. ADVERSE REACTIONS**

Isolated cases of adverse reactions typically associated with non-steroidal anti-inflammatory drugs (NSAIDs) were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible.

In very rare cases loss of appetite, lethargy, abdominal pain and colitis have been reported.  
In very rare cases anaphylactoid reactions which may be serious (including fatal) may occur and should be treated symptomatically

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Horses.

## **8. DOSE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Dosage

Oral suspension to be administered at a dosage of 0.6 mg/kg body weight, once daily, up to 14 days. This is equivalent to 1 ml of Inlacam per 25 kg body weight of horse. For example, a horse weighing 400 kg will receive 16 ml of Inlacam, a horse weighing 500 kg will receive 20 ml of Inlacam, and a horse weighing 600 kg will receive 24 ml of Inlacam.

### Method and route of administration

Shake well before use. To be administered either mixed with a small quantity of food, prior to feeding, or directly into the mouth.

The suspension should be given using the measuring syringe provided in the package. The syringe fits onto the bottle and has a 2 ml scale.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD(S)**

Meat and offal: 3 days.

Not authorised for use in lactating animals producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

After administration of the veterinary medicinal product, close the bottle by replacing the cap, wash the measuring syringe with warm water and let it dry.

Do not use after the expiry date (EXP) stated on the carton and the bottle.

Shelf life after first opening of the container: 3 months.

## **12. SPECIAL WARNING(S)**

### Special precautions for use in animals:

If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.

Use during pregnancy and lactation:

See the section under “Contraindications”.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents.

Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose symptomatic treatment should be initiated.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

**15. OTHER INFORMATION**

To be supplied only on veterinary prescription.

100 or 250 ml bottle with a measuring syringe.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**  
Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**  
VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**  
VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**  
VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**  
Virbac Danmark  
A/S, Profilvej 1, DK-6000  
Kolding, Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**  
VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**  
VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)800 73 09 10

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**PACKAGE LEAFLET:**  
Inflacam 1 mg chewable tablets for dogs  
Inflacam 2.5 mg chewable tablets for dogs

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd.

Loughrea,  
Co. Galway,  
Ireland.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 1 mg chewable tablets for dogs  
Inflacam 2.5 mg chewable tablets for dogs  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One chewable tablet contains:

Active substance

Meloxicam 1 mg

Meloxicam 2.5 mg

**4. INDICATION(S)**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.

**5. CONTRAINDICATIONS**

Do not use in pregnant or lactating animals.

Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

**6. ADVERSE REACTIONS**

Typical adverse drug reactions of non-steroidal anti-inflammatory drugs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases, haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Dogs

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.

Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively.

Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal.

Inflacam chewable tablets can be administered with or without food, are flavoured and are taken by most dogs voluntarily.

Dose scheme for the maintenance dose:

Body weight (kg)	Number of chewable tablets		mg/kg
	1 mg	2.5 mg	
4.0–7.0	½		0.13–0.1
7.1–10.0	1		0.14–0.1
10.1–15.0	1½		0.15–0.1
15.1–20.0	2		0.13–0.1
20.1–25.0		1	0.12–0.1
25.1–35.0		1½	0.15–0.1
35.1–50.0		2	0.14–0.1

The use of Inflacam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg the use of Inflacam oral suspension for dogs is recommended.

A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.

## **9. ADVICE ON CORRECT ADMINISTRATION**

To ensure correct dosage, body weight should be determined as accurately as possible to avoid underdosing or overdosing.

## **10. WITHDRAWAL PERIOD(S)**

Not applicable

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

## **12. SPECIAL WARNING(S)**

### Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.

### Use during pregnancy and lactation:

See section "Contraindications".

### Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inflacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.

### Overdose (symptoms, emergency procedures, antidotes):

In case of overdose symptomatic treatment should be initiated.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

## **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

## **15. OTHER INFORMATION**

Package sizes:

20 tablets

100 tablets

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**  
Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**  
VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**  
VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**  
VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**  
Virbac Danmark  
A/S, Profilvej 1, DK-6000  
Kolding, Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**  
VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**  
VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)800 73 09 10

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

## PACKAGE LEAFLET:

### Inflacam 5 mg/ml solution for injection for dogs and cats

#### **1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway,  
Ireland

Manufacturers responsible for the batch release:

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway,  
Ireland

and

Eurovet Animal Health B.V.  
Handelsweg 25, 5531 AE Bladel,  
The Netherlands

and

Labiana Life Sciences, S.A., C/ Venus, 26, Pol. Ind. Can Parellada, Tarrasa, 08228 Barcelona

#### **2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for dogs and cats  
Meloxicam

#### **3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One ml contains:

Meloxicam 5 mg,  
Ethanol (96%) 159.8 mg.  
Clear, yellow solution.

#### **4. INDICATION(S)**

Dogs:

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

## **5. CONTRAINDICATIONS**

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

## **6. ADVERSE REACTIONS**

Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure, have occasionally been reported. In very rare cases elevated liver enzymes have been reported.

In very rare cases, haemorrhagic diarrhoea, haematemesis, and gastrointestinal ulceration have been reported.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment, but in very rare cases may be serious or fatal.

In very rare cases, anaphylactoid reactions may occur and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Dogs and cats.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Dosage for each species

Dogs: single administration of 0.2 mg meloxicam /kg body weight (i.e. 0.4 ml/10 kg).

Cats: single administration of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg).

### Method and routes of administration

#### Dogs:

Musculo-skeletal disorders: single subcutaneous injection.

Inflacam 1.5 mg/ml oral suspension for dogs or Inflacam 1 mg and 2.5 mg chewable tablets for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example, at the time of induction of anaesthesia.

#### Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example, at the time of induction of anaesthesia.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Particular care should be taken with regard to the accuracy of dosing.  
Avoid introduction of contamination during use.  
Maximum number of piercings is 42 for all presentations.

## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.  
Keep the vial in the outer carton.  
Do not use after the expiry date (EXP) stated on the carton and vial.  
Shelf life after first opening the container: 28 days.

## **12. SPECIAL WARNING(S)**

### Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

### Use during pregnancy and lactation:

Do not use in pregnant or lactating animals.

### Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anti-coagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inlacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g., aged animals), intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

### Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose, symptomatic treatment should be initiated.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**15. OTHER INFORMATION**

Carton box containing one colourless glass injection vial of 10 ml, 20 ml or 100ml, closed with a bromobutyl rubber stopper and sealed with an aluminium cap.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**

VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**

VIRBAC Danmark A/S  
Profilvervej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**

VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**

Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**

VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**

VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**

VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**

VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**

Virbac Danmark  
A/S, Profilvervej 1,  
DK-6000 Kolding,  
Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**

VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**

VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)805 05 55 55

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**PACKAGE LEAFLET:**  
**Inflacam 5 mg/ml solution for injection for cattle and pigs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway, Ireland

Manufacturers responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea, Co. Galway, Ireland

and

Eurovet Animal Health B.V.  
Handelsweg 25, 5531 AE Bladel, The Netherlands

and

Labiana Life Sciences, S.A., C/ Venus, 26, Pol. Ind. Can Parellada, Tarrasa, 08228 Barcelona

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 5 mg/ml solution for injection for cattle and pigs  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS**

One ml contains:

Meloxicam	5 mg,
Ethanol (96%)	159.8 mg.

Clear, yellow solution.

**4. INDICATION(S)**

Cattle

For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.

For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.

For the relief of post-operative pain following dehorning in calves.

Pigs

For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.  
For the relief of post-operative pain associated with minor soft tissue such as castration.

## **5. CONTRAINDICATIONS**

Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of ulcerogenic gastrointestinal lesions.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

For the treatment of diarrhoea in cattle, do not use in animals of less than one week of age.

Do not use in pigs less than 2 days old.

## **6. ADVERSE REACTIONS**

A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.

In very rare cases anaphylactoid reactions which may be serious (including fatal) may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Cattle (calves and young cattle) and pigs.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

### Cattle

Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 10 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate.

### Pigs

#### Locomotor disorders:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/25 kg body weight). If required, a second administration of meloxicam can be given after 24 hours.

#### Reduction of post-operative pain:

Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 0.4 ml/5 kg body weight) before surgery.

Particular care should be taken with regard to the accuracy of dosing including the use of an appropriate dosing device and careful estimation of bodyweight.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD(S)**

Cattle: meat and offal: 15 days.

Pigs: meat and offal: 5 days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use after the expiry date (EXP) stated on the carton and vial.

Shelf life after first opening the container: 28 days.

## **12. SPECIAL WARNING(S)**

Treatment of calves with Inflacam 20 minutes before dehorning reduces post-operative pain. Inflacam alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Treatment of piglets with Inflacam before castration reduces post-operative pain. To obtain pain relief during surgery co-medication with an appropriate anaesthetic/sedative is needed.

To obtain the best possible relieving effect post-surgery Inlacam should be administered 30 minutes before surgical intervention.

### Special precautions for use in animals:

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Accidental self-injection may give rise to pain. People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

### Use during pregnancy and lactation:

Cattle: Can be used during pregnancy.

Pigs: Can be used during pregnancy and lactation.

### Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anticoagulant agents.

### Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose symptomatic treatment should be initiated.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

#### **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

#### **15. OTHER INFORMATION**

Cardboard box containing 1 colourless glass injection vial of 20 ml, 50 ml or 100 ml.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**  
Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**  
VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**  
VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**  
VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**  
Virbac Danmark  
A/S, Profilvej 1, DK-6000  
Kolding, Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**  
VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**  
VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)800 73 09 10

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**PACKAGE LEAFLET:**  
**Inflacam 330 mg granules for horses**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
IRELAND.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 330 mg granules for horses.  
Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One sachet contains: 330 mg of meloxicam.  
Pale yellow granules.

**4. INDICATION(S)**

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in horses weighing between 500 and 600 kg.

**5. CONTRAINDICATIONS**

Do not use in pregnant or lactating mares.  
Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.  
Do not use in case of hypersensitivity to the active substance or to any of the excipients.  
Do not use in horses less than 6 weeks of age.

**6. ADVERSE REACTIONS**

Isolated cases of adverse reactions typically associated with non-steroidal anti-inflammatory drugs (NSAIDs) were observed in clinical trials (slight urticaria, diarrhoea). Symptoms were reversible. In very rare cases loss of appetite, lethargy, abdominal pain and colitis have been reported.

In very rare cases anaphylactoid reactions, which may be serious (including fatal), may occur and should be treated symptomatically.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Horses.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

In-feed use.

To be administered mixed with food at a dose of 0.6 mg/kg body weight, once daily, up to 14 days. The product should be added to 250 g of muesli feed, prior to feeding.

Each sachet contains one dose for a horse weighing between 500 kg and 600 kg and the dose must not be divided into smaller doses.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD(S)**

Meat and offal: 3 days.

Not authorised for use in lactating animals producing milk for human consumption.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the sachet after EXP.

Shelf life after incorporation into muesli feed: use immediately.

## **12. SPECIAL WARNING(S)**

### Special precautions for use in animals:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

In order to minimise risk of intolerance, the product should be mixed into muesli feed.

This product is only for use in horses weighing between 500 and 600 kg.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.

Pregnancy and lactation:

Do not use in pregnant or lactating mares.

Interaction with other medicinal products and other forms of interaction:

Do not administer concurrently with glucocorticoids, other NSAIDs or with anti-coagulant agents.

Overdose (symptoms, emergency procedures, antidotes):

In the case of overdose symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

**15. OTHER INFORMATION**

Pack size: 20 and 100 sachets.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**  
Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**  
VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**  
VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**  
VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**  
Virbac Danmark  
A/S, Profilvej 1, DK-6000  
Kolding, Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**  
VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**  
VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)800 73 09 10

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**PACKAGE LEAFLET:**  
**Inflacam 0.5 mg/ml oral suspension for cats**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd.,  
Loughrea,  
Co. Galway,  
IRELAND.

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Inflacam 0.5 mg/ml oral suspension for cats.  
meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

One ml contains:

Active substance

Meloxicam 0.5 mg.

Excipient

Sodium benzoate 1.5 mg.

Smooth light yellow suspension

**4. INDICATION(S)**

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.

Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.

**5. CONTRAINDICATIONS**

Do not use in pregnant or lactating animals.

Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cats less than 6 weeks of age.

**6. ADVERSE REACTIONS**

Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. Gastrointestinal ulceration and elevated liver enzymes were reported in very rare cases.

These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Cats.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Oral use.

### Post-operative pain and inflammation following surgical procedures:

After initial treatment with Inlacam 5 mg/ml solution for injection for cats, continue treatment 24 hours later with Inlacam 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight (0.1 ml /kg). The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to 4 days.

### Acute musculo-skeletal disorders:

Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight (0.4 ml/kg) on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a dose of 0.05 mg meloxicam/kg body weight (0.1 ml /kg) for as long as acute pain and inflammation persist.

### Chronic musculo-skeletal disorders:

Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight (0.2 ml/kg) on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight (0.1 ml /kg).

A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent.

### Route and method of administration

A one ml syringe is provided with the product. The precision of the syringe is not suitable for the treatment of cats below 1 kg.

Shake well before use. To be administered orally either mixed with food or directly into the mouth.

## **9. ADVICE ON CORRECT ADMINISTRATION**

Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded.

Please carefully follow the instructions of the veterinarian.

Avoid introduction of contamination during use.

## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after EXP.

Shelf life after first opening of the container:

3 ml and 5 ml bottles: 14 days

10 ml and 15 ml bottles: 6 months.

## **12. SPECIAL WARNING(S)**

Special precautions for use in animals:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.

Post-operative pain and inflammation following surgical procedures:

In case additional pain relief is required, multimodal pain therapy should be considered.

Chronic musculoskeletal disorders:

Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show this package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. See section "Contraindications".

Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inlacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic veterinary medicinal products should be avoided.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose (symptoms, emergency procedures, antidotes):

Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.

In case of overdose, adverse reactions, as listed in section "Adverse reactions", are expected to be more severe and more frequent. In case of overdose symptomatic treatment should be initiated.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary products.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIAL, IF ANY**

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu>).

**15. OTHER INFORMATION**

Pack size: 1 x 3 ml, 1 x 5 ml, 1 x 10 ml or 1 x 15 ml bottle with a measuring syringe.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tel: + 32-(0) 16 38 72 60  
info@virbac.be

**Република България**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Тел: +33-(0)4 92 08 73 00

**Česká republika**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tel: + 45-(0)7552 1244

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: + 49-(0)(4531) 805 111

**Eesti**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prantsusmaa  
Tel: +33-(0)4 92 08 73 00

**Ελλάδα**  
Virbac Hellas AE  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμιάς,  
EL-14452, Μεταμόρφωση  
Τηλ.: + 30-(0)210 6219520  
E-mail: [info@virbac.gr](mailto:info@virbac.gr)

**España**  
VIRBAC ESPAÑA, SA Angel Guimerá 179-181,  
ES-08950 - Esplugues de Llobregat (Barcelona)  
Tel: + 34-(0) 93 470 79 40

**Lietuva**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Prancūzija  
Tel: +33-(0)4 92 08 73 00

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM N.V.  
Esperantolaan 4  
BE-3001 Leuven, Belgium  
Tel: + 32-(0) 16 38 72 60

**Magyarország**  
VIRBAC HUNGARY KFT  
Szent István krt.11.II/21.  
HU-1055 Budapest  
Tel: +36-(0)703387177

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m – L.I.D  
MT-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Nederland**  
VIRBAC NEDERLAND BV  
Hermesweg 15  
NL-3771  
ND-Barneveld  
Tel: + 31-(0) 342 427 127  
info@virbac.nl

**Norge**  
Virbac Danmark  
A/S, Profilvej 1, DK-6000  
Kolding, Danmark,  
Tel: + 45-(0)7552 1244

**Österreich**  
VIRBAC Österreich GmbH  
Hildebrandgasse 27  
AT-1180 Wien  
Tel: + 43-(0) 1 21 834 260

**Polska**  
VIRBAC Sp. z o.o.  
ul. Puławska 314  
02-819 Warszawa  
Tel.: + 48-(0)22 855 40 46

**France**

VIRBAC France  
13<sup>e</sup> rue – LID –  
FR-06517 Carros Cedex  
France  
Tél : +33-(0)800 73 09 10

**Ireland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0)4 92 08 73 00

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39-(0)02 40 92 47 1

**Κύπρος**

VIRBAC HELLAS A.E.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30-(0)2106219520  
[info@virbac.gr](mailto:info@virbac.gr)

**Latvija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francjia  
Tel: +33-(0)4 92 08 73 00

**România**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
RO-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Portugal**

VIRBAC DE Portugal  
LABORATÓRIOS LDA  
R.do Centro Empresarial  
Ed13-Piso 1- Esc.3  
Quinta da Beloura  
PT-2710-693 Sintra  
Tel.: + 35-(0)1 219 245 020

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Slovenská republika**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Suomi/Finland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FI-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00

**Sverige**

Virbac Danmark A/S Filial Sverige,  
SE-171 21 Solna  
Tel: + 45-(0)7552 1244

**United Kingdom (Northern Ireland)**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
France  
Tel: + 33-(0)4 92 08 73 00

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m – LID  
FR-06516 Carros, France  
Tel: + 33-(0) 4 92 08 73 00